Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Precision oncology, driven by genomics, has advanced cancer therapy but benefits limited patients (10-20%).
• Genomic approaches face challenges in understanding complex cancer biology and drug resistance mechanisms.
• There is a critical need for complementary strategies to broaden the reach of precision oncology.

Purpose of the Study:

• To review the current state and limitations of genomics-driven precision oncology.
• To highlight the potential of proteomics-based strategies for patient selection and overcoming drug resistance.
• To explore the utility of Reverse-Phase Protein Arrays (RPPA) in advancing precision oncology.

Main Methods:

• Review of current literature on precision oncology, genomics, and proteomics.
• Focus on the application and advantages of RPPA technology.
• Analysis of clinical trial examples demonstrating RPPA's utility.

Main Results:

• Genomics-driven precision oncology has limitations in patient applicability and addressing drug resistance.
• Proteomics offers deeper insights into cancer pathogenesis and biomarker discovery.
• RPPA technology enables quantitative protein analysis, even with limited samples, and aids in understanding drug response and resistance.

Conclusions:

• Integrating proteomics, especially RPPA, is crucial for the next phase of precision oncology.
• RPPA can establish robust biomarker-drug associations and help overcome therapeutic challenges.
• RPPA facilitates a deeper understanding of molecular mechanisms driving treatment outcomes and resistance.